Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors of esophageal cancer, a highly deadly cancer for which a diagnosis is ...

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a price ...

Shares of Lucid Diagnostics (NASDAQ:LUCD) fell over 14% premarket on Tuesday after the company launched a stock offering to raise approximately $15.3M in gross proceeds. The diagnostics company has ...

Lucid Diagnostics (LUCD) announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of ...

(RTTNews) - Lucid Diagnostics Inc. (LUCD), a US-based commercial-stage cancer prevention diagnostics company and a subsidiary of PAVmed Inc., has regained compliance with the Nasdaq Capital Market ...

Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...

Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy The ENVET-BE study reviewed real-world data from a ...

About Lucid Diagnostics Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions ...